Cargando…

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

SPN‐812 (viloxazine extended‐release) is a novel nonstimulant recently approved as a treatment for attention‐deficit/hyperactivity disorder in children and adolescents. Given that SPN‐812 is metabolized by CYP2D6 and may be coadministered with CYP2D6 inhibitors, this trial investigated the pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhao, Kosheleff, Alisa R., Adeojo, Lilian W., Odebo, Oyinkansola, Adewole, Toyin, Qin, Peibing, Maletic, Vladimir, Schwabe, Stefan, Nasser, Azmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597116/ https://www.ncbi.nlm.nih.gov/pubmed/33943033 http://dx.doi.org/10.1002/cpdd.948

Ejemplares similares

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
por: Johnson, Janet K., et al.
Publicado: (2019)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
por: Yu, Chungping, et al.
Publicado: (2020)

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
por: Findling, Robert L., et al.
Publicado: (2021)

Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2023)

Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Morphologic and molecular characterization of new Cyclospora species from Ethiopian monkeys: C. cercopitheci sp.n., C. colobi sp.n., and C. papionis sp.n.
por: Eberhard, M L, et al.
Publicado: (1999)

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2021)

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Structural Studies of the Spinosyn Forosaminyltransferase, SpnP
por: Isiorho, Eta A., et al.
Publicado: (2014)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
por: Faraone, Stephen V., et al.
Publicado: (2021)

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
por: Nasser, Azmi, et al.
Publicado: (2021)

Paroxetine overdose
por: Gupta, Arun K., et al.
Publicado: (2005)

In vitro pharmacological characterization of SPN-810M (molindone)
por: Yu, Chungping, et al.
Publicado: (2018)

Editorial: Meeting of the Portuguese Society for Neurosciences SPN2019
por: Diógenes, Maria José, et al.
Publicado: (2021)

Französische Suiten, BWV 812-817 French suites = Suites françaises /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1995)

Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats
por: Hernández-Arrambide, Pedro Efraín, et al.
Publicado: (2022)

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree(®)): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2023)

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
por: Nasser, Azmi, et al.
Publicado: (2022)

AN EMBEDDING TECHNIQUE FOR ELECTRON MICROSCOPY USING EPON 812
por: Craig, Elson L., et al.
Publicado: (1962)

Paroxetine-induced galactorrhea
por: Gulati, Prannay, et al.
Publicado: (2014)

Paroxetine-induced galactorrhea
por: Petrykiv, S., et al.
Publicado: (2022)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation
por: Moudi, Emadouddin, et al.
Publicado: (2016)

Development of glycinergic innervation to the murine LSO and SPN in the presence and absence of the MNTB
por: Altieri, Stefanie C., et al.
Publicado: (2014)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

Paroxetine overdose during pregnancy
por: Acar, Selin, et al.
Publicado: (2021)

Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials
por: Singh, Alok, et al.
Publicado: (2022)

Role of Standardized Perfusion Value (SPV) in the characterization of Solitary Pulmonary Nodules (SPN)
por: Reginelli, A, et al.
Publicado: (2011)

The Structure of SpnF, a Standalone Enzyme that Catalyzes [4+2] Cycloaddition
por: Fage, Christopher D., et al.
Publicado: (2015)

The elongation factor Spn1 is a multi-functional chromatin binding protein
por: Li, Sha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rpem9arkg2mfvh8r9rcj7bsihq